Catalyst Pharmaceuticals Valuation
| CPRX Stock | USD 15.14 0.15 1.00% |
At this time, the firm appears to be overvalued. Catalyst Pharmaceuticals shows a prevailing Real Value of $12.64 per share. The current price of the firm is $15.14. Our model approximates the value of Catalyst Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 1.65 B, return on equity of 0.21, and Profit Margin of 0.18 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend. Key fundamental drivers impacting Catalyst Pharmaceuticals' valuation include:
Price Book 4.6306 | Enterprise Value 1.7 B | Enterprise Value Ebitda 13.8859 | Price Sales 4.5106 | Forward PE 10.352 |
Overvalued
Today
Please note that Catalyst Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Catalyst Pharmaceuticals is based on 3 months time horizon. Increasing Catalyst Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Catalyst Pharmaceuticals is useful when determining the fair value of the Catalyst stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Catalyst Pharmaceuticals. Since Catalyst Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Catalyst Stock. However, Catalyst Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.14 | Real 12.64 | Target 23.1 | Hype 14.99 | Naive 14.38 |
The real value of Catalyst Stock, also known as its intrinsic value, is the underlying worth of Catalyst Pharmaceuticals Company, which is reflected in its stock price. It is based on Catalyst Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Catalyst Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Catalyst Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Catalyst Pharmaceuticals helps investors to forecast how Catalyst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Catalyst Pharmaceuticals more accurately as focusing exclusively on Catalyst Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Catalyst Pharmaceuticals' intrinsic value based on its ongoing forecasts of Catalyst Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Catalyst Pharmaceuticals' closest peers. When choosing an evaluation method for Catalyst Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Catalyst Pharmaceuticals Investments |
|
Catalyst Valuation Trend
Knowing Catalyst Pharmaceuticals' actual value is paramount for traders to make sound investment determinations. Catalyst Pharmaceuticals' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Catalyst Pharmaceuticals' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Catalyst Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Catalyst Market Cap
Catalyst Pharmaceuticals is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 76.02 Billion. Catalyst Pharmaceuticals holds roughly 1.79 Billion in market capitalization claiming about 2.35% of equities under Health Care industry.Catalyst Pharmaceuticals Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catalyst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catalyst Pharmaceuticals competition to find correlations between indicators driving Catalyst Pharmaceuticals's intrinsic value. More Info.Catalyst Pharmaceuticals is rated second in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about 0.20 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Catalyst Pharmaceuticals is roughly 5.10 . Price To Book Ratio is likely to drop to 4.38 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Catalyst Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Catalyst Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Catalyst Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Catalyst Pharmaceuticals and how it compares across the competition.
About Catalyst Pharmaceuticals Valuation
The stock valuation mechanism determines the current worth of Catalyst Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Catalyst Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Catalyst Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Catalyst Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Catalyst Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Catalyst Pharmaceuticals. We calculate exposure to Catalyst Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Catalyst Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 313.7 M | 329.4 M | |
| Pretax Profit Margin | 0.24 | 0.25 | |
| Operating Profit Margin | 0.22 | 0.23 | |
| Net Profit Margin | 0.18 | 0.19 | |
| Gross Profit Margin | 0.79 | 0.92 |
8 Steps to conduct Catalyst Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Catalyst Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Catalyst Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Catalyst Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Catalyst Pharmaceuticals' revenue streams: Identify Catalyst Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Catalyst Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Catalyst Pharmaceuticals' growth potential: Evaluate Catalyst Pharmaceuticals' management, business model, and growth potential.
- Determine Catalyst Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Catalyst Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Catalyst Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Catalyst Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 113.8 M | |
| Quarterly Earnings Growth Y O Y | 0.346 | |
| Forward Price Earnings | 10.352 |
Catalyst Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Catalyst Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Catalyst we look at many different elements of the entity such as Catalyst's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Catalyst Pharmaceuticals' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Catalyst Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Catalyst Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Catalyst Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Catalyst Pharmaceuticals' worth.When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.